Ranibizumab Intravitreal Injections in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion

Inclusion Criteria:

• Male or female patients ≥ 18 years of age

• Diagnosis of visual impairment exclusively due to ME secondary to CRVO

• BCVA score at Screening and Baseline between 73 and 19 letters Early TreatmentDiabetic Retinopathy Study (ETDRS), inclusively (approximate Snellen chart equivalentof 20/40 and 20/400)

Exclusion Criteria:

• Uncontrolled blood pressure defined as systolic value of > 160 mm Hg or diastolicvalue of > 100 mm Hg at Screening or Baseline.

• Any active periocular or ocular infection or inflammation at Screening or Baseline ineither eye

• Uncontrolled glaucoma at Screening or Baseline or diagnosed within 6 months beforeBaseline in either eye

• Use of any systemic antivascular endothelial growth factor (anti-VEGF) drugs within 6months before Baseline (eg, sorafenib [Nexavar®], sunitinib [Sutent®], bevacizumab [Avastin®])